Mustafa Abu Salim
Department of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait.
Vaccines (Basel). 2021 Aug 30;9(9):972. doi: 10.3390/vaccines9090972.
The only licensed vaccine against tuberculosis is BCG. However, BCG has failed to provide consistent protection against tuberculosis, especially pulmonary disease in adults. Furthermore, the use of BCG is contraindicated in immunocompromised subjects. The research towards the development of new vaccines against TB includes the use of antigens as subunit vaccines. Such vaccines may be used either alone or in the prime-boost model in BCG-vaccinated people. However, the antigens for subunit vaccines require adjuvants and/or delivery systems to induce appropriate and protective immune responses against tuberculosis and other diseases. Articles published in this Special Issue have studied the pathogenesis of BCG in children and the use of BCG and recombinant BCG as potential vaccines against asthma. Furthermore, the use of different adjuvants and delivery systems in inducing the protective immune responses after immunization with subunit vaccines has been described.
唯一获得许可的抗结核疫苗是卡介苗（BCG）。然而，卡介苗未能始终如一地提供针对结核病的保护，尤其是对成人肺结核的保护。此外，免疫功能低下的人群禁忌使用卡介苗。研发新型抗结核疫苗的研究包括使用抗原作为亚单位疫苗。此类疫苗可单独使用，也可在接种卡介苗的人群中采用初免-加强免疫模式使用。然而，亚单位疫苗的抗原需要佐剂和/或递送系统来诱导针对结核病和其他疾病的适当且具有保护性的免疫反应。本期特刊发表的文章研究了卡介苗在儿童中的发病机制，以及卡介苗和重组卡介苗作为抗哮喘潜在疫苗的应用。此外，还描述了在亚单位疫苗免疫后使用不同佐剂和递送系统诱导保护性免疫反应的情况。
